Group 1 - The core stock price of Bid Pharma on July 30 was 59.06 yuan, down by 2.42 yuan, representing a decline of 3.94% [1] - The trading volume on the same day was 100 million yuan, with a turnover rate of 3.84%, and the total market capitalization stood at 5.368 billion yuan [1] - Bid Pharma specializes in the biopharmaceutical sector, focusing on pharmaceutical research and development services, and operates within the bioproducts and CRO industry segments [1] Group 2 - The company will hold its fourth extraordinary general meeting of shareholders for 2025 on July 31 to discuss multiple proposals, including changes to its business scope, the cancellation of the supervisory board, and amendments to the company’s articles of association [1] - The meeting will take place at the conference room on the 6th floor of Building 3, No. 999 Xiangyin Road, Yangpu District, Shanghai [1] - On July 30, the net outflow of main funds was 15.3766 million yuan, accounting for 0.6% of the circulating market value [1]

Group 1 - The stock price of Jinkai Biotechnology is reported at 39.28 yuan as of July 30, 2025, reflecting a decline of 1.73% from the previous trading day [1] - The trading volume on the same day reached 263 million yuan, with a turnover rate of 11.73% [1] - Jinkai Biotechnology's main business includes bioproducts, weight loss drugs, and CRO services, and the company is part of the Liaoning sector with specialized and innovative qualifications [1] Group 2 - Shareholder Qilu Investment has reduced its holdings by a total of 4,477,700 shares between December 18, 2024, and July 28, 2025, accounting for 3.72% of the total share capital, bringing its ownership down to 4.99996% [1] - On July 30, 2025, the net outflow of main funds was 27.78 million yuan [1]

Group 1 - The company held its 30th meeting of the 5th Board of Directors on July 30, 2025, via telecommunication, with all 10 directors present, confirming compliance with legal and regulatory requirements [1] - The Board approved the signing of an amendment to the Exclusive Sublicense Agreement with Notitia Biotechnologies Company, granting the company exclusive rights to develop, manufacture, and commercialize core microbiome analysis, microbiome-targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1][2] - The Board also approved the application for credit facilities from several banks, including China Construction Bank, China Merchants Bank, Agricultural Bank of China, and others, to support the company's and its subsidiaries' research, production, sales, and daily operational expenses [2][6] Group 2 - The approved credit facilities will include comprehensive credit, working capital loans, project loans, bank acceptance bills, and guarantees, all of which will be unsecured [3][4][5] - The financial department is authorized to determine financing methods, amounts, terms, and interest rates within the approved credit limits, with legal representatives signing relevant contracts and documents [6]

证券代码：300142 证券简称：沃森生物 公告编号：2025-037 云南沃森生物技术股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届监事会第二十一 次会议于 2025 年 7 月 30 日以通讯表决的方式召开，会议通知于 7 月 27 日以电子 邮件方式发出。本次会议应参会监事 3 人，实际参加会议监事 3 人。会议由监事 会主席丁世青女士主持。本次会议的召集、召开符合《公司法》及《公司章程》 的规定。 二、监事会会议审议情况 审议通过了《关于公司及子公司向银行申请授信额度的议案》 监事会同意公司及子公司玉溪沃森生物技术有限公司（以下简称"玉溪沃 森"）、玉溪泽润生物技术有限公司（以下简称"玉溪泽润"）根据业务发展及 日常运营需要，向中国建设银行股份有限公司玉溪市分行（以下简称"建设银行"）、 招商银行股份有限公司昆明分行（以下简称"招商银行"）、中国农业银行股份 有限公司玉溪分行（以下简称"农业银行"）、中国光大银行股份有限公司昆明 分行（以下简称"光大银行"）、 ...

山东未名生物医药股份有限公司 董事和高级管理人员离职管理制度 （经 2025 年 7 月 30 日召开的第六届董事会第四次会议审议通过） 第一章 总 则 第一条 为规范山东未名生物医药股份有限公司（以下简称公司）董事和高 级管理人员离职程序，确保公司治理结构的稳定性和连续性，维护公司及股东的 合法权益，根据《中华人民共和国公司法》（以下简称《公司法》）《中华人民 共和国证券法》（以下简称《证券法》）《上市公司治理准则》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》等法律、行政法规、部门规章、规范性文件以及《公司章程》的 有关规定，结合公司实际情况，制定本管理制度。 第二条 本制度适用于公司董事（含独立董事）、高级管理人员因任期届满、 辞职、被解除职务、退休或其他原因离职的情形。 第二章 离职情形与程序 第三条 董事可以在任期届满以前辞任。董事辞任应当向公司提交书面辞职 报告，公司收到辞职报告之日辞任生效，公司将在两个交易日内披露有关情况。 如因董事的辞任导致公司董事会成员低于法定最低人数、独立董事人数少于董事 会成员的三分之一或者独立董事中没有会计专 ...

Core Points - The document outlines the work system for the Secretary of the Board of Directors of Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to enhance corporate governance and the role of the board secretary [1][2] - The board secretary is a senior management position responsible for communication with the Shenzhen Stock Exchange and managing shareholder and board meeting preparations [2][3] Section Summaries General Provisions - The board secretary is designated as the contact person for the company with the Shenzhen Stock Exchange and is responsible for various administrative tasks related to board and shareholder meetings [2][3] Qualifications - The board secretary must possess necessary financial, management, and legal knowledge, and must hold a qualification certificate recognized by the Shenzhen Stock Exchange [3] Responsibilities and Duties - The board secretary is responsible for managing information disclosure, coordinating investor relations, and ensuring compliance with relevant regulations [5][6] - The secretary must maintain confidentiality regarding undisclosed significant information and report any leaks to the exchange promptly [5][6] - The board secretary also oversees the management of the company's stock and related transactions [4][5] Appointment Procedures - The board secretary is nominated by the chairman and appointed by the board, with specific documentation required for the appointment [8][9] - In case of vacancy, the board must appoint an interim secretary and complete the hiring process within a specified timeframe [9] Legal Responsibilities - The board secretary shares liability for decisions that violate laws or regulations, but can be exempted if they can prove dissenting opinions were expressed [10][10]

General Principles - The document outlines the stamp management system of Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to standardize and streamline the management of stamps to protect the company's legal rights [1][2] - The system applies to the company, its subsidiaries, and departments regarding the management and use of various stamps [1] Types of Stamps - The types of stamps include company seals, legal representative seals, financial seals, contract seals, board seals, departmental seals, and electronic seals, all of which have legal validity [1][2] - Specific uses for each type of stamp are defined, such as the company seal for important documents and the legal representative seal for official certifications [2] Stamp Creation and Approval - The creation of stamps must follow legal procedures and be approved by designated authorities within the company [3][4] - Different stamps have specific approval processes, such as the board seal requiring approval from the board secretary and chairman [3][4] Stamp Custody - A separation of duties and decentralized custody system is established for stamp management, ensuring that stamp custodians do not personally approve their own usage [4] - Designated personnel are responsible for the custody of different types of stamps, with a requirement for proper documentation and reporting in case of loss or damage [4][5] Stamp Usage - A pre-approval and registration system is in place for stamp usage, requiring departments to submit requests that must be approved by authorized personnel [5][6] - Stamps should not be used on incomplete documents or blank forms, and any unauthorized use will be reported and addressed [6][7] Stamp Abolition and Destruction - Procedures for abolishing and destroying stamps are outlined, including the need for approval and proper documentation when stamps are no longer in use [7][8] - Stamps that are required for ongoing legal or business matters must be retained until those matters are resolved [8] Responsibilities - Unauthorized creation or use of stamps is strictly prohibited, with consequences for individuals who violate these rules [8][9] - Stamp custodians are responsible for the safe keeping of stamps and must report any loss or unauthorized use immediately [9]

General Principles - The financial management system of Shandong Weiming Biological Pharmaceutical Co., Ltd. aims to standardize accounting recognition, measurement, and reporting to ensure the quality of accounting information and improve economic efficiency while protecting shareholders' rights [1][2][3] Financial Management Structure and Personnel - The company has established a financial management organization under the leadership of the board of directors, with the general manager responsible for implementation [2][3] - A planning finance center is set up to handle financial management and accounting matters, staffed with qualified accounting personnel [2][3] - The company has the authority to appoint and dismiss financial heads of its subsidiaries, while other financial personnel are hired according to internal regulations [2][3] Accounting Policies and Estimates - The company adopts a calendar year as its accounting period, running from January 1 to December 31 [3][4] - The functional currency for accounting is determined based on the primary economic environment, with RMB used for companies established in mainland China [4][5] - The company uses the accrual basis of accounting and historical cost for measurement [4][5] Financial Asset Recognition and Measurement - Financial assets are classified at initial recognition into categories such as amortized cost, fair value through other comprehensive income, and fair value through profit or loss [5][6] - The company assesses credit risk and recognizes impairment losses based on expected credit losses [8] Inventory Accounting - Inventory is initially measured at cost and includes raw materials, finished goods, work in progress, and low-value consumables [9] - The company uses the weighted average method for inventory issuance and recognizes impairment when the cost exceeds the net realizable value [9] Long-term Equity Investment Accounting - The company uses the cost method for subsequent measurement of long-term equity investments in subsidiaries and adjusts for equity method in consolidated financial statements [10] Fixed Assets and Depreciation - Fixed assets are recorded at actual cost and depreciated using the average annual method based on asset categories [11][12] Intangible Assets Accounting - Intangible assets are initially measured at cost, including purchase price and related expenses, and are amortized over their useful lives [13][14] Revenue Recognition - Revenue is recognized when control of the goods is transferred to the customer, and specific criteria must be met [21] Tax Accounting - The company uses the balance sheet liability method for income tax accounting, recognizing deferred tax assets or liabilities based on differences between the book value and tax base of assets and liabilities [17] Financial Reporting - The company prepares financial reports including balance sheets, income statements, cash flow statements, and changes in equity statements, adhering to relevant accounting standards [23][24][25]

General Principles - The purpose of the management system is to strengthen control over subsidiaries, standardize internal operations, protect the rights of the company and investors, and promote healthy development of subsidiaries [1][2] - The company maintains a relationship of equal legal status with its subsidiaries, exercising shareholder rights and providing guidance and supervision [2][3] - The system aims to enhance risk control, improve operational efficiency, and increase the company's overall risk resistance [2][3] Personnel Management - The company, as the main investor, exercises shareholder rights through the subsidiary's shareholders' meeting and appoints representatives and management [4][5] - Personnel appointed by the company must adhere to legal obligations and cannot exploit their positions for personal gain [5][6] - Training is provided to subsidiary management to ensure compliance with relevant laws and company regulations [5][6] Financial Management - Subsidiaries must comply with national fiscal and tax policies and establish their own financial management systems [7][8] - The company supervises the financial management of subsidiaries and requires timely reporting of financial statements [8][9] - Subsidiaries must adhere to the company's accounting policies and ensure the legality and accuracy of financial data [8][9] Operational Decision-Making - Subsidiaries must align their operational plans with the company's overall strategy and adhere to legal regulations [10][11] - Major transactions exceeding the subsidiary's authority require approval from the company's management [10][11] - Subsidiaries are responsible for conducting due diligence and feasibility studies before making investment decisions [11][12] Information Disclosure - Subsidiaries must follow the company's information disclosure policies and report significant matters promptly [12][13] - Meetings held by subsidiaries must be reported to the company for approval and documentation [13][14] - The company requires accurate and timely reporting of operational and financial information from subsidiaries [14][15] Internal Audit and Supervision - The company conducts regular audits of subsidiaries to ensure compliance with laws and internal regulations [15][16] - Subsidiaries must cooperate with audits and implement corrective measures for identified issues [15][16] - The internal audit system of the company applies to subsidiaries, ensuring accountability and transparency [16][17] Assessment and Rewards - Subsidiaries are required to establish their own assessment and reward systems based on the company's guidelines [17][18] - Annual assessments of senior management are conducted based on performance metrics and audit results [17][18] - The company reserves the right to impose penalties on subsidiary management for failing to fulfill their responsibilities [18]

Core Viewpoint - The internal control system of Shandong Weiming Biological Pharmaceutical Co., Ltd. aims to enhance corporate governance, ensure compliance, protect investor rights, and promote sustainable development through a structured framework [1][2]. Group 1: General Principles - The internal control system is designed to ensure legal compliance, asset security, and the authenticity of financial reporting [1]. - The board of directors is responsible for the establishment, implementation, and improvement of the internal control system, with regular evaluations of its effectiveness [1][2]. Group 2: Basic Requirements - Internal control should consider elements such as internal environment, risk assessment, control activities, information communication, and internal supervision [2]. - The company must establish a governance structure that promotes effective decision-making and risk awareness [3]. Group 3: Control Activities - Internal control activities must cover all business segments related to financial reporting and information disclosure, including sales, procurement, inventory, and asset management [3]. - The company must ensure that its assets are independently owned and not misappropriated by controlling shareholders or related parties [4]. Group 4: Risk Management - A comprehensive risk assessment system should be established to monitor various risks, including operational, financial, market, regulatory, and ethical risks [5]. - The company should implement a robust internal audit function to evaluate the effectiveness of internal controls and report findings to the board [6][16]. Group 5: Subsidiary Management - The company must develop control policies for subsidiaries, ensuring they establish their own internal control systems based on their business characteristics [6]. - Regular performance evaluations and financial reporting from subsidiaries are required to maintain oversight [6]. Group 6: Related Party Transactions - Internal controls for related party transactions must adhere to principles of honesty, equality, and fairness, ensuring no harm to the company or its shareholders [7]. - The company must establish clear approval processes for related party transactions, including the requirement for independent directors to review such matters [8]. Group 7: External Guarantees and Fund Management - The company must manage external guarantees with a focus on legality, prudence, and mutual benefit, ensuring risks are controlled [9]. - A management framework for the use of raised funds must be established, ensuring compliance with stated purposes and effective tracking of fund usage [12][13]. Group 8: Major Investments and Information Disclosure - Major investments should be subject to rigorous evaluation and approval processes to mitigate risks and ensure effective returns [14]. - The company must maintain a robust information disclosure system to report significant events that could impact stock prices [15]. Group 9: Internal Audit and Evaluation - The internal audit department is responsible for assessing the completeness and effectiveness of internal controls across the company and its subsidiaries [16]. - Regular internal control evaluations should be conducted, with findings reported to the board for necessary actions [17][18].